Cytek Biosciences (CTKB) | Stock Overview & Key Data
Cytek Biosciences Performance Comparison
Stock Range
Today's Range
Low: $3.43
High: $3.66
on August 1, 2025
52 Week Range
Low: $2.37
High: $7.63
on May 23, 2025
on November 7, 2024
All-Time High: $28.70 on September 13, 2021
Explore how other US stocks compare to their 52-week ranges: View US Market 52-Week Insights
Key Statistics
Market Cap
$461.0M
EPS
-0.09
P/E Ratio (TTM)
374.50
Forward P/E
60.67
P/B Ratio
1.22
PEG Ratio
60.67
Div. Yield
N/A
ROE
-2.91%
Beta
1.337
Debt to Equity
4.19
Financial Highlights
Profitability
Gross Margin
48.62%
Operating Margin
-36.12%
Profit Margin
-5.71%
Returns and Earnings
Return on Assets (TTM)
-3.51%
Return on Equity (TTM)
-2.91%
EBITDA
$-20.0M
Net Income (TTM)
$-11.3M
Growth
Revenue (TTM)
Revenue Per Share (TTM)
$1.53
Quarterly Revenue Growth (YoY)
-7.60%
Quarterly Earnings Growth (YoY)
-7.59%
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Cytek Biosciences CTKB | 461.04M Small-cap | -1.36% | 4.60% | -1.62% | -32.47% | -44.60% | -39.93% | -75.78% | -80.60% |
| Abbott Laboratories ABT | 221.54B Mega-cap | 0.59% | -6.58% | -2.74% | -0.90% | 12.21% | 14.36% | 16.51% | 25.74% |
| Boston Scientific BSX | 155.95B Large-cap | -0.69% | 0.60% | 2.15% | 2.27% | 17.93% | 41.49% | 157.47% | 170.49% |
| UFP Technologies UFPT | 1.75B Small-cap | -6.35% | -10.22% | 6.71% | -16.34% | -7.98% | -28.36% | 154.14% | 406.53% |
| Conmed CNMD | 1.62B Small-cap | 2.63% | -3.29% | -8.57% | -26.57% | -22.36% | -23.85% | -46.10% | -38.46% |
| QuidelOrtho QDEL | 1.54B Small-cap | -16.72% | -23.43% | -18.19% | -46.37% | -49.36% | -45.70% | -75.26% | -91.64% |
Ownership & Short Interest
Insider Ownership
9.15%
Institutional Ownership
61.85%
Shares Short
6M
Short Ratio
4.54
Short % of Shares Outstanding
5.81%
Average 10-Day Volume
950K
Average 90-Day Volume
1M
Cytek Biosciences Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in Cytek Biosciences would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is CTKB's 52-week high and low?
- In the last 52 weeks, Cytek Biosciences reached a high of $7.63 (on November 7, 2024) and a low of $2.37 (on May 23, 2025).
- What is the market cap and P/E ratio for CTKB?
- Curious about Cytek Biosciences's size and valuation? Its market capitalization stands at 461.04M. When it comes to valuation, the P/E ratio (trailing twelve months) is 374.50, and the forward P/E (looking ahead) is 60.67.
- Does CTKB pay dividends? If so, what's the yield?
- As for dividends, Cytek Biosciences isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Cytek Biosciences's main competitors or similar companies to consider before investing?
When looking at Cytek Biosciences, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Abbott Laboratories
ABT221.54B Healthcare Medical Devices 14.36% 16.51% Boston Scientific
BSX155.95B Healthcare Medical Devices 41.49% 157.47% UFP Technologies
UFPT1.75B Healthcare Medical Devices -28.36% 154.14% Conmed
CNMD1.62B Healthcare Medical Devices -23.85% -46.10% QuidelOrtho
QDEL1.54B Healthcare Medical Devices -45.70% -75.26% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Cytek Biosciences Inc.? (e.g., ROE, Debt/Equity)
- To get a sense of Cytek Biosciences's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is -2.91%, the Debt to Equity ratio from the most recent quarter is 4.19, and its Gross Profit Margin stands at 48.62%.
- What is the recent revenue and earnings growth for CTKB?
- Looking at Cytek Biosciences's growth, its revenue over the trailing twelve months (TTM) was $197M. Compared to the same quarter last year (YoY), quarterly revenue grew by -7.60%, and quarterly earnings saw a YoY growth of -7.59%.
- How much of CTKB stock is held by insiders and institutions?
- Wondering who owns Cytek Biosciences stock? Company insiders (like executives and directors) hold about 9.15% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 61.85%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.